Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy
Solid Biosciences has come up with a $50 million crossover round that would appear to be positioning the company for an IPO as it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
